Last edition
News about "Minjae Shin"
Kaigene Licenses Autoimmune Drug KG006 to Taisho Pharma in Japan
Taisho Pharmaceutical secures exclusive rights to clinically develop, register, and commercialise Kaigene's next-generation FcRn inhibitor, KG006, in Japan.
Minjae Shin | 01/08/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members